HomeCompareCAMRF vs MCD

CAMRF vs MCD: Dividend Comparison 2026

CAMRF yields 3.64% · MCD yields 2.35%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 MCD wins by $53.2K in total portfolio value· pulled ahead in Year 4
10 years
CAMRF
CAMRF
● Live price
3.64%
Share price
$55.00
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$25.3K
Annual income
$459.40
Full CAMRF calculator →
MCD
McDonald's Corporation
● Live price
2.35%
Share price
$308.53
Annual div
$7.26
5Y div CAGR
42.3%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$78.5K
Annual income
$26,227.70
Full MCD calculator →

Portfolio growth — CAMRF vs MCD

📍 MCD pulled ahead of the other in Year 4

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodCAMRFMCD
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, CAMRF + MCD cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
CAMRF pays
MCD pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

CAMRF
Annual income on $10K today (after 15% tax)
$309.09/yr
After 10yr DRIP, annual income (after tax)
$390.49/yr
MCD
Annual income on $10K today (after 15% tax)
$200.01/yr
After 10yr DRIP, annual income (after tax)
$22,293.55/yr
At 15% tax rate, MCD beats the other by $21,903.05/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of CAMRF + MCD for your $10,000?

CAMRF: 50%MCD: 50%
100% MCD50/50100% CAMRF
Portfolio after 10yr
$51.9K
Annual income
$13,343.55/yr
Blended yield
25.69%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on MCD right now

CAMRF
No analyst data
Altman Z
39.4
Piotroski
5/9
MCD
Analyst Ratings
37
Buy
23
Hold
1
Sell
Consensus: Buy
Price Target
$351.76
+14.0% upside vs current
Range: $320.00 — $385.00
Altman Z
4.9
Piotroski
5/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

CAMRF buys
0
MCD buys
0
No recent congressional trades found for CAMRF or MCD in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricCAMRFMCD
Forward yield3.64%2.35%
Annual dividend / share$2.00$7.26
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%42.3%
Portfolio after 10y$25.3K$78.5K
Annual income after 10y$459.40$26,227.70
Total dividends collected$4.1K$58.5K
Payment frequencyquarterlyquarterly
SectorStockConsumer Discretionary

Year-by-year: CAMRF vs MCD ($10,000, DRIP)

YearCAMRF PortfolioCAMRF Income/yrMCD PortfolioMCD Income/yrGap
1$11,064$363.64$10,815$334.85+$249.00CAMRF
2$12,214$375.99$11,826$491.71+$388.00CAMRF
3$13,457$387.94$13,123$730.06+$334.00CAMRF
4← crossover$14,798$399.45$14,853$1,100.07$55.00MCD
5$16,245$410.53$17,257$1,690.61$1.0KMCD
6$17,803$421.18$20,752$2,667.01$2.9KMCD
7$19,481$431.38$26,103$4,354.83$6.6KMCD
8$21,286$441.15$34,794$7,437.78$13.5KMCD
9$23,226$450.49$49,926$13,461.60$26.7KMCD
10$25,311$459.40$78,550$26,227.70$53.2KMCD

CAMRF vs MCD: Complete Analysis 2026

CAMRFStock

Camurus AB (publ), a pharmaceutical company, develops and commercializes medicines for severe and chronic conditions in Europe, Australia, the United States, Japan, and internationally. The company offers Buvidal, a buprenorphine injection for the treatment of opioid dependence; episil oral liquid, a medical device for the treatment of inflammatory and painful conditions in the oral cavity; and Brixadi to treat opioid use disorder Its products pipeline also includes CAM2038 for the treatment of chronic pain; CAM2029, which is in phase III clinical trials for the treatment of acromegaly and neuroendocrine tumors, as well as in phase II clinical trial to treat polycystic liver diseases; and CAM2043 that is in phase I clinical trial for the treatment of pulmonary arterial hypertension, as well as in Phase II clinical trial to treat Raynaud's phenomenon. In addition, the company is developing CAM2032, which is in phase II clinical trials for the treatment of prostate cancer; CAM4072 that is in phase III clinical trials for the treatment of genetic obesity disorders; CAM4071, which is in phase I clinical trials for the treatment of endocrine disorder; CAM2047 for the treatment of chemotherapy-induced nausea and vomiting that is in phase 1 clinical trial; and CAM2048, which is in phase I clinical trial for postoperative pain. Camurus AB (publ) was founded in 1991 and is headquartered in Lund, Sweden.

Full CAMRF Calculator →

MCDConsumer Discretionary

McDonald's Corporation operates and franchises McDonald's restaurants in the United States and internationally. Its restaurants offer hamburgers and cheeseburgers, chicken sandwiches and nuggets, wraps, fries, salads, oatmeal, shakes, desserts, sundaes, soft serve cones, bakery items, soft drinks, coffee, and beverages and other beverages, as well as breakfast menu, including biscuit and bagel sandwiches, breakfast burritos, hotcakes, and other sandwiches. As of December 31, 2021, the company operated 40,031 restaurants. McDonald's Corporation was founded in 1940 and is headquartered in Chicago, Illinois.

Full MCD Calculator →
📬

Get this CAMRF vs MCD comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

CAMRF vs SCHDCAMRF vs JEPICAMRF vs OCAMRF vs KOCAMRF vs MAINCAMRF vs YUMCAMRF vs QSRCAMRF vs SBUX

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.